Competing Stats

WE ARE COMMITTED to empowering you as you strive to continue providing the highest quality diagnostic information for patients. Discover innovations to diagnose and treat patients more personally: www.company.com IHC market share With nearly 70% of IHC market share in the US, we empower you to deliver the industry's leading solutions for cancer diagnostics. Competitor B 12% Company 66% Competitor A 14% Assays Company is committed to filling unmet medical needs with a robust menu of 297 clinically valuable assays. 297 107 119 Company Competitor A Competitor B IHC/ISH platforms We empower more labs worldwide to improve accuracy and time to result with fully automated IHC/ISH staining platforms. 23%6 Company Competitor A Competitor B 10% 16% Pasient Patient Dokter Doctor Tonts IHC/ISH platforms We empower more US labs to improve accuracy and time to result with fully automated IHC/ISH staining platforms. 49% 49% 27% 15% Company Competitor A Competitor B R&D We invest heavily in R&D, so you 15% can diagnose and treat patients more personally. 5.0 Company 10% Competitor A 7% Competitor B Source: Boston Biomedical Consulting (BBC) 2011 Data.